Clinical trial
A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease
NCT06111014 is registered in ClinicalTrials.gov with Alector Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease
- Lead sponsor
- Alector Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 8, 2023
- Completion date
- January 7, 2026
- Enrollment
- 17 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.